Dr Richard Hopkins

Managing Director ex USA, Zelira Therapeutics


Dr Hopkins is an experienced bio-pharmaceutical executive with over 20 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel therapies with a particular focus in oncology, corporate strategy, business development and intellectual property.

Dr Hopkins is currently the Managing Director ex-USA at Zelira Therapeutics, a leading global company focused on clinical validation of medical cannabis. Prior to this, Dr Hopkins served as Chief Executive Officer at PharmAust where he oversaw clinical development of a novel cancer therapy for dogs and humans. He was also a co-founder of Phylogica, where, in addition to the CEO role, he served in variety of positions, including Chief Scientific Officer, and Chief Operating Officer where he led a team of over 25 scientists.

During his career, Dr. Hopkins and managed and overseen strategic alliances and licensing deals with multiple global pharmaceutical partners including J&J, Pfizer, Roche, Genentech, AstraZeneca/Medimmune, generated over $14 million in revenues and built strong proprietary pipelines.

Dr Hopkins is an author on over 30 peer reviewed publications and is an inventor on 17 patents and patent applications.

Back to Speakers

Zelira Therapeutics

ZELIRA Therapeutics is a global biopharmaceutical company developing and marketing clinically validated cannabinoid-based medicines targeting insomnia and autism.
Read more
Join Us!

Register your interest to attend and stay up to date with our latest news.